Glycyrrhizic acid inhibits apoptosis and fibrosis in carbontetrachloride-induced rat liver injury

World Journal of Gastroenterology

Volumn 21, Issue 17, 2015, Pages 5271-5280

  Liang, Bo ^a   Guo, Xiao Ling ^a   Jin, Jing ^b   Ma, Yong Chun ^a   Feng, Zheng Quan ^a  

^a TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Glycyrrhizic acid; Hepatic stellate cell; Hepatocyte apoptosis; Liver fibrosis; Matrix metalloproteinase

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; GLYCYRRHIZIC ACID; MESSENGER RNA; PROTEIN BAX; ACTIN; BAX PROTEIN, RAT; CASP3 PROTEIN, RAT; CTGF PROTEIN, RAT; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; PROTECTIVE AGENT; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; COLLAGEN FIBER; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HYPERPLASIA; LIVER CELL; LIVER INJURY; LIVER LOBULE; LIVER SLICE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CELL PROTECTION; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HEPATIC STELLATE CELL; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARBON TETRACHLORIDE; CASPASE 3; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; CYTOPROTECTION; GLYCYRRHIZIC ACID; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84929000101     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i17.5271     Document Type: Article

References (41)

1. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548 [PMID: 17332881 DOI: 10.1172/JCI30542]
2. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654 [PMID: 15084697 DOI: 10.1056/NEJMra035021]
3. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002; 37: 400-410 [PMID: 12175638]
4. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights 2012; 7: 105-117 [PMID: 22872786 DOI: 10.4137/BMI.S10009]
5. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-1330 [PMID: 12360492]
6. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273-278 [PMID: 14767974 DOI: 10.1002/hep.20051]
7. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Kanto T, Hiramatsu N, Kubota S, Takigawa M, Tomimaru Y, Tomokuni A, Nagano H, Doki Y, Mori M, Hayashi N. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011; 121: 3343-3356 [PMID: 21747166 DOI: 10.1172/JCI44957]
8. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006; 43: S82-S88 [PMID: 16447275 DOI: 10.1002/hep.20974]
9. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525-1528 [PMID: 11984538]
10. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417 [PMID: 22043231 DOI: 10.1177/17 56283X11413002]
11. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-1306 [PMID: 19711424 DOI: 10.1002/hep.23123]
12. Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B. Cochrane Database Syst Rev 2001; (1): CD001940 [PMID: 11279742 DOI: 10.1002/14651858.CD001940]
13. Dang SS, Zhang X, Jia XL, Cheng YA, Song P, Liu EQ, He Q, Li ZF. Protective effects of emodin and astragalus polysaccharides on chronic hepatic injury in rats. Chin Med J (Engl) 2008; 121: 1010-1014 [PMID: 18706249]
14. Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T, Watanabe A, Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 1996; 30: 171-177 [PMID: 8783808]
15. Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38- dependent mitochondrial pathway. World J Gastroenterol 2012; 18: 679-684 [PMID: 22363140 DOI: 10.3748/wjg.v18.i7.679]
16. Ikeda T, Abe K, Kuroda N, Kida Y, Inoue H, Wake K, Morito M, Sato T. The inhibition of apoptosis by glycyrrhizin in hepatic injury induced by injection of lipopolysaccharide /D-galactosamine in mice. Arch Histol Cytol 2008; 71: 163-178 [PMID: 19194039]
17. Guo XL, Liang B, Wang XW, Fan FG, Jin J, Lan R, Yang JH, Wang XC, Jin L, Cao Q. Glycyrrhizic acid attenuates CCl4-induced hepatocyte apoptosis in rats via a p53-mediated pathway. World J Gastroenterol 2013; 19: 3781-3791 [PMID: 23840116 DOI: 10.3748/wjg.v19.i24.3781]
18. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108 [PMID: 18546601]
19. Mantena SK, Sharma SD, Katiyar SK. Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis 2006; 27: 2018-2027 [PMID: 16621886 DOI: 10.1093/carcin/bgl043]
20. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-1500 [PMID: 9118029]
21. van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizininduced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432-2437 [PMID: 11513186 DOI: 10.1111/j.1572-0241.2001.04049.x]
22. Shi J, Aisaki K, Ikawa Y, Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 1998; 153: 515-525 [PMID: 9708811 DOI: 10.1016/S0002-9440(10)65594-0]
23. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G137-G144 [PMID: 16123203 DOI: 10.1152/ajpgi.00080.2005]
24. Aram G, Potter JJ, Liu X, Wang L, Torbenson MS, Mezey E. Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration. Hepatology 2009; 49: 911-919 [PMID: 19072832 DOI: 10.1002/hep.22708]
25. Kuwahata M, Kubota H, Kanouchi H, Ito S, Ogawa A, Kobayashi Y, Kido Y. Supplementation with branched-chain amino acids attenuates hepatic apoptosis in rats with chronic liver disease. Nutr Res 2012; 32: 522-529 [PMID: 22901560 DOI: 10.1016/j.nutres.2012.06.007]
26. Lee TY, Chang HH, Wang GJ, Chiu JH, Yang YY, Lin HC. Water-soluble extract of Salvia miltiorrhiza ameliorates carbon tetrachloride-mediated hepatic apoptosis in rats. J Pharm Pharmacol 2006; 58: 659-665 [PMID: 16640835 DOI: 10.1211/jpp.58.5.0011]
27. Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Z Gastroenterol 2007; 45: 43-50 [PMID: 17236120 DOI: 10.1055/s-2006-927387]
28. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-136 [PMID: 12708612 DOI: 10.1080/713611034]
29. Liu C, Wang G, Chen G, Mu Y, Zhang L, Hu X, Sun M, Liu C, Liu P. Huangqi decoction inhibits apoptosis and fibrosis, but promotes Kupffer cell activation in dimethylnitrosamine-induced rat liver fibrosis. BMC Complement Altern Med 2012; 12: 51 [PMID: 22531084 DOI: 10.1186/1472-6882-12-51]
30. Friedman SL. Me chani sms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
31. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105 [PMID: 16265071 DOI: 10.1038/ncpgasthep0055]
32. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 677-683 [PMID: 8938545]
33. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185]
34. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-372 [PMID: 11586465 DOI: 10.1055/s-2001-17556]
35. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-719 [PMID: 421999]
36. Nakatsukasa H, Nagy P, Evarts RP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factorbeta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990; 85: 1833-1843 [PMID: 1693377 DOI: 10.1172/JCI114643]
37. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210 [PMID: 18161745 DOI: 10.1002/path.2277]
38. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361-368 [PMID: 19768189]
39. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008; 233: 109-122 [PMID: 18222966 DOI: 10.3181/0707-MR-190]
40. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710 [PMID: 17629588 DOI: 10.1016/j.jhep.2007.05.015]
41. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-1079 [PMID: 18783549 DOI: 10.1111/j.1478-3231.2008.01826.x]